Dravite Therapeutics discloses $53M financing without naming a drug program
Founded in 2025, Dravite Therapeutics has reported nearly $68M in equity sales across two offerings; its filings do not identify a drug program or participating investors.
By RuntimeWire Staff · Published
Primary source: U.S. Securities and Exchange Commission
Why it matters
Dravite has reported nearly $68M in equity sales within months of its first filing, while its investors, valuation, use of proceeds and drug program remain undisclosed.
Dravite Therapeutics, a San Francisco biotech led by President and CEO Matthew Moore, disclosed a $52,999,992 equity financing from 11 investors in a Form D filed September 3rd.
The offering was fully sold, according to the filing, with the first sale occurring on August 21st. Dravite issued equity under Rule 506(b) and reported no sales commissions or finders' fees. The filing does not identify the investors, a lead backer, the valuation or the planned use of proceeds.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.